Publications

Orfali N, O'Donovan TR, Nyhan MJ, Britschgi A, Tschan MP, Cahill MR, Mongan NP, Gudas LJ, McKenna SL.  2015.  Induction of autophagy is a key component of all-trans-retinoic acid-induced differentiation in leukemia cells and a potential target for pharmacologic modulation.. Exp Hematol. 43(9):781-93.e2.

Raman JD, Mongan NP, Tickoo SK, Boorjian SA, Scherr DS, Gudas LJ.  2005.  Increased expression of the polycomb group gene, EZH2, in transitional cell carcinoma of the bladder.. Clin Cancer Res. 11(24 Pt 1):8570-6.

Martinez-Ceballos E, Gudas LJ.  2008.  Hoxa1 is required for the retinoic acid-induced differentiation of embryonic stem cells into neurons.. J Neurosci Res. 86(13):2809-19.

van der Mijn JC, Eng KW, Chandra P, Fernandez E, Ramazanoglu S, Sigaras A, Oromendia C, Gudas LJ, Tagawa ST, Nanus DM et al..  2022.  The genomic landscape of metastatic clear cell renal cell carcinoma after systemic therapy.. Mol Oncol.

van der Mijn JC, Eng KW, Chandra P, Fernandez E, Ramazanoglu S, Sigaras A, Oromendia C, Gudas LJ, Tagawa ST, Nanus DM et al..  2022.  The genomic landscape of metastatic clear cell renal cell carcinoma after systemic therapy.. Mol Oncol.

Fu L, Minton DR, Zhang T, Nanus DM, Gudas LJ.  2015.  Genome-Wide Profiling of TRACK Kidneys Shows Similarity to the Human ccRCC Transcriptome.. Mol Cancer Res. 13(5):870-8.

Melis M, Tang X-H, Mai K, Gudas LJ, Trasino SE.  2022.  Fenretinide Reduces Intestinal Mucin-2-Positive Goblet Cells in Chronic Alcohol Abuse.. Pharmacology. :1-11.

Melis M, Tang X-H, Mai K, Gudas LJ, Trasino SE.  2022.  Fenretinide Reduces Intestinal Mucin-2-Positive Goblet Cells in Chronic Alcohol Abuse.. Pharmacology. :1-11.

Tang X-H, Marta M, Gudas LJ, Mai K, Trasino SE.  2021.  Fenretinide Improves Intestinal Barrier Function and Mitigates Alcohol Liver Disease. Front. Pharmacol.

Tang X-H, Marta M, Gudas LJ, Mai K, Trasino SE.  2021.  Fenretinide Improves Intestinal Barrier Function and Mitigates Alcohol Liver Disease. Front. Pharmacol.

Kopparapu PKumar, Boorjian SA, Robinson BD, Downes M, Gudas LJ, Mongan NP, Persson JL.  2013.  Expression of VEGF and its receptors VEGFR1/VEGFR2 is associated with invasiveness of bladder cancer.. Anticancer Res. 33(6):2381-90.

Kopparapu PKumar, Boorjian SA, Robinson BD, Downes M, Gudas LJ, Mongan NP, Persson JL.  2013.  Expression of cyclin d1 and its association with disease characteristics in bladder cancer.. Anticancer Res. 33(12):5235-42.

Harris AE, Metzler VM, Lothion-Roy J, Varun D, Woodcock CL, Haigh DB, Endeley C, Haque M, Toss MS, Alsaleem M et al..  2022.  Exploring anti-androgen therapies in hormone dependent prostate cancer and new therapeutic routes for castration resistant prostate cancer.. Front Endocrinol (Lausanne). 13:1006101.

Harris AE, Metzler VM, Lothion-Roy J, Varun D, Woodcock CL, Haigh DB, Endeley C, Haque M, Toss MS, Alsaleem M et al..  2022.  Exploring anti-androgen therapies in hormone dependent prostate cancer and new therapeutic routes for castration resistant prostate cancer.. Front Endocrinol (Lausanne). 13:1006101.

Harris AE, Metzler VM, Lothion-Roy J, Varun D, Woodcock CL, Haigh DB, Endeley C, Haque M, Toss MS, Alsaleem M et al..  2022.  Exploring anti-androgen therapies in hormone dependent prostate cancer and new therapeutic routes for castration resistant prostate cancer.. Front Endocrinol (Lausanne). 13:1006101.

Harris AE, Metzler VM, Lothion-Roy J, Varun D, Woodcock CL, Haigh DB, Endeley C, Haque M, Toss MS, Alsaleem M et al..  2022.  Exploring anti-androgen therapies in hormone dependent prostate cancer and new therapeutic routes for castration resistant prostate cancer.. Front Endocrinol (Lausanne). 13:1006101.

Harris AE, Metzler VM, Lothion-Roy J, Varun D, Woodcock CL, Haigh DB, Endeley C, Haque M, Toss MS, Alsaleem M et al..  2022.  Exploring anti-androgen therapies in hormone dependent prostate cancer and new therapeutic routes for castration resistant prostate cancer.. Front Endocrinol (Lausanne). 13:1006101.

Kauffman EC, Robinson BD, Downes M, Marcinkiewicz K, Vourganti S, Scherr DS, Gudas LJ, Mongan NP.  2013.  Estrogen receptor-β expression and pharmacological targeting in bladder cancer.. Oncol Rep. 30(1):131-8.

Kauffman EC, Robinson BD, Downes M, Marcinkiewicz K, Vourganti S, Scherr DS, Gudas LJ, Mongan NP.  2013.  Estrogen receptor-β expression and pharmacological targeting in bladder cancer.. Oncol Rep. 30(1):131-8.

Melis M, Tang X-H, Trasino SE, Patel VM, Stummer DJ, Jessurun J, Gudas LJ.  2019.  Effects of AM80 compared to AC261066 in a high fat diet mouse model of liver disease.. PLoS One. 14(1):e0211071.

Malkovskiy AV, Van Wassenhove LD, Goltsev Y, Osei-Sarfo K, Chen C-H, Efron B, Gudas LJ, Mochly-Rosen D, Rajadas J.  2021.  The Effect of Ethanol Consumption on Composition and Morphology of Femur Cortical Bone in Wild-Type and ALDH2*2-Homozygous Mice.. Calcif Tissue Int. 108(2):265-276.

Malkovskiy AV, Van Wassenhove LD, Goltsev Y, Osei-Sarfo K, Chen C-H, Efron B, Gudas LJ, Mochly-Rosen D, Rajadas J.  2021.  The Effect of Ethanol Consumption on Composition and Morphology of Femur Cortical Bone in Wild-Type and ALDH2*2-Homozygous Mice.. Calcif Tissue Int. 108(2):265-276.

Mongan NP, Gudas LJ.  2007.  Diverse actions of retinoid receptors in cancer prevention and treatment.. Differentiation. 75(9):853-70.

Martinez-Ceballos E, Chambon P, Gudas LJ.  2005.  Differences in gene expression between wild type and Hoxa1 knockout embryonic stem cells after retinoic acid treatment or leukemia inhibitory factor (LIF) removal.. J Biol Chem. 280(16):16484-98.

Raman JD, Mongan NP, Liu L, Tickoo SK, Nanus DM, Scherr DS, Gudas LJ.  2006.  Decreased expression of the human stem cell marker, Rex-1 (zfp-42), in renal cell carcinoma.. Carcinogenesis. 27(3):499-507.